Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial)

This publication has 40 references indexed in Scilit:

• A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
  Annals of Oncology, 2005
• Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
  Annals of Oncology, 2005
• Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma
  Cancer, 2005
• Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine
  Cancer, 2004
• Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
  Annals of Oncology, 2002
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
  European Journal Of Cancer, 1999
• Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
  European Journal Of Cancer, 1997
• A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer
  Cancer, 1992
• High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer
  European Journal of Cancer and Clinical Oncology, 1988